Sunesis Pharmaceuticals – Consensus Indicates Potential 77.6% Upside

Broker Ratings

Sunesis Pharmaceuticals with ticker code (SNSS) now have 2 analysts in total covering the stock. The consensus rating is ‘Hold’. The target price ranges between 5 and 1.5 with the average target price sitting at 3.25. Given that the stocks previous close was at 1.83 this would indicate that there is a potential upside of 77.6%. The 50 day MA is 1.53 and the 200 day MA is 2.3. The company has a market cap of $33m. Find out more information at: http://www.sunesis.com

Sunesis Pharmaceuticals, a biopharmaceutical company, focuses on the development and commercialization of targeted inhibitors for the treatment of hematologic and solid cancers. Its lead product candidate is vecabrutinib, a non-covalent inhibitor of Bruton’s tyrosine kinase (BTK), which is in Phase 1b/2 clinical trial for the treatment of chronic lymphocytic leukemia, mantle cell lymphoma, and other B-cell malignancies. The company is also developing SNS-510, which is in preclinical pharmacology studies for the treatment of solid tumor and hematologic malignancies; various other partnered programs, such as TAK-580, a pan-Raf inhibitor program that is in Phase 1 clinical trial for the treatment of pediatric low-grade glioma; and vosaroxin, an anti-cancer quinolone derivative that intercalates DNA and inhibits topoisomerase II. It has a collaboration agreement with Biogen Idec MA to discover, develop, and commercialize small molecule BTK inhibitors; and license agreement with Takeda Pharmaceutical Company Limited to develop and commercialize preclinical inhibitors of PDK1. Sunesis Pharmaceuticals was founded in 1998 and is headquartered in South San Francisco, California.

You can now share this on Stocktwits, just click the logo below and add the ticker in the text to be seen.

Share on Stocktwits

Good news travels fast (but only if you make that happen):

Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on facebook
Facebook
Share on email
Email
Share on reddit
Reddit

AIM All Share Index